Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Afatinib-refractory brain metastases from EGFR-mutant non-small-cell lung cancer successfully controlled with erlotinib: a case report.

Anti-cancer drugs - 1 Mar 2016

Nonagase Yoshikane, Okamoto Kunio, Iwasa Tsutomu, Yoshida Takeshi, Tanaka Kaoru, Takeda Masayuki, Kaneda Hiroyasu, Shimizu Toshio, Tsurutani Junji, Nakagawa Kazuhiko

Abstract excerpt

Both afatinib and erlotinib are tyrosine kinase inhibitors that inhibit aberrant epidermal growth factor receptor (EGFR) signals in non-small-cell lung cancer (NSCLC). Afatinib is an irreversible inhibitor directed against EGFR, ErbB-2, and ErbB-4, whereas erlotinib is a reversible inhibitor directed against EGFR only. Although afatinib has been shown to be effective in the treatment for erlotinib-refractory...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Afatinib
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Brain Neoplasms

Share to Carcinoma, Non-Small-Cell Lung

Share to Combined Modality Therapy

Share to ErbB Receptors

Share to Erlotinib Hydrochloride

Share to Quinazolines

Source

Identifiers

PMID: 26575001
DOI: 10.1097/CAD.0000000000000317

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Afatinib-refractory brain metastases from EGFR-mutant non-small-cell lung cancer successfully controlled with erlotinib: a case report.PMID 26575001Read ↗

Afatinib in Treatment-Naive Patients With EGFR-Mutated Lung Adenocarcinoma With Brain Metastasis: A Case Series.Semantic proximity Read ↗

Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease.Semantic proximity Read ↗

Response to afatinib in treatment-naïve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases.Semantic proximity Read ↗

Overcoming T790M-driven acquired resistance to EGFR-TKIs in NSCLC with afatinib: a case report.Semantic proximity Read ↗

Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease.Semantic proximity Read ↗

Commentary: Treatment Considerations for Patients With Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Brain Metastases in the Era of Tyrosine Kinase Inhibitors.Semantic proximity Read ↗

First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.Semantic proximity Read ↗

Combination treatment with bevacizumab plus erlotinib for meningeal carcinomatosis of afatinib-resistant EGFR mutated lung cancer without T790M mutation: a case report.Semantic proximity Read ↗

The effectiveness of erlotinib against brain metastases in non-small cell lung cancer patients.Semantic proximity Read ↗

Erlotinib for the treatment of brain metastases in non-small cell lung cancer.Semantic proximity Read ↗

Clinical Efficacy of Afatinib Treatment for a Patient with Leptomeningeal Carcinomatosis.Semantic proximity Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.